The rumors swirling around the “end” of Medicare Part D are a classic case of technical evolution being mistaken for extinction. As we move into late 2026, the program isn’t being deleted; it’s undergoing a massive structural overhaul that feels like a total redesign for anyone who’s been managing their own coverage for years. The biggest headline is the final elimination of the “coverage gap,” better known as the donut hole, which has haunted seniors since the program’s inception. In its place, the Inflation Reduction Act has mandated a hard out-of-pocket cap of $2,100 for 2026.
However, the “getting rid of” part of the story comes from a different angle: the collapse of the standalone Part D plan market. We’ve seen a staggering 31% decrease in the number of standalone drug plans being offered between 2025 and 2026 alone. Many insurers are pulling out of the market entirely because the new $2,100 cap shifts much more financial risk onto the insurance companies and away from the government. For those of us who prefer to keep our Original Medicare with a standalone drug plan, the choices are becoming increasingly slim.
There’s also a major policy shift coming from the administration regarding how these plans are subsidized. In 2025, a premium stabilization demonstration was launched to help insurers adjust to these new caps without spiking premiums. But as of late 2026, the administration has announced this subsidy program will end by 2027. This means that while out-of-pocket drug costs are capped at $2,100, the monthly premiums you pay to keep the plan could see a significant jump next year. It’s a classic DevOps-style trade-off: we’ve optimized the user-facing cost of drugs, but the infrastructure costs (premiums) are rising to compensate.